Carcinotech Ltd

Carcinotech Ltd is a MedTech company founded in 2018 and headquartered in the United Kingdom. The company's slogan, "Reinventing Cancer Research," reflects its mission to revolutionize cancer treatment through innovative technology.

Carcinotech specializes in manufacturing 3D printed micro-tumours using patient-derived biopsies, primary cells, immune cells, and cancer stem cells. This advanced approach provides a platform for rapid, ethical, and accurate drug screening, pre-clinical, and personalized medicine testing.

With a focus on collaboration, Carcinotech works with global partners, leading pharma companies, surgeons, pathologists, clinicians, and industry leaders to accelerate drug screening and bring more effective cancer treatments to market. The company's expertise in robotic and automated manufacturing enables accelerated production with high-throughput capabilities.

The latest milestone for Carcinotech is the £4.20M Seed Round investment on 29 January 2024, led by a syndicate of investors including Maven Capital Partners, SIS Ventures, Scottish Enterprise, Eos, Edinburgh Innovations, Alba Equity, TRICAPITAL Angels Limited, Gabriel Investments, and Investing Women.

With a team of like-minded, highly experienced individuals, Carcinotech is poised for success in reshaping the landscape of cancer research and treatment. The company's innovative models and collaborative approach position it as a key player in the biotechnology industry.